TCI Wealth Advisors’s Seres Therapeutics MCRB Stock Holding History

TCI Wealth Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27	Closed	-$3.05K	–	2594
2022 Q4	$3.05K	Buy	+27	New	+$3.62K	﹤0.01%	1851
2022 Q2	–	Sell	-26	Closed	-$4K	–	2426
2022 Q1	$4K	Sell	26 -1	-4%	-$154	﹤0.01%	1734
2021 Q4	$4K	Buy	+27	New	+$4.29K	﹤0.01%	1850
2021 Q3	–	Sell	-7	Closed	-$3K	–	2496
2021 Q2	$3K	Buy	7 +2	+40%	+$844	﹤0.01%	1795
2021 Q1	$2K	Buy	+5	New	+$2.3K	﹤0.01%	1805

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCI Wealth Advisors's MCRB Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Seres Therapeutics (MCRB) in Q1 2023, closing a stake of 27 shares — an estimated $3.05K sold.

TCI Wealth Advisors first reported a position in MCRB in Q1 2021 and held it in 5 quarters. The position peaked at $4K in Q1 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q1 2023.

TCI Wealth Advisors reported no remaining Seres Therapeutics position as of Q1 2023 after selling out during the quarter.
TCI Wealth Advisors sold 27 Seres Therapeutics shares in Q1 2023, an estimated $3.05K.
TCI Wealth Advisors first reported a position in Seres Therapeutics in Q1 2021 and held it in 5 quarters.
TCI Wealth Advisors's Seres Therapeutics position peaked at $4K in Q1 2022.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.